Head-to-head · WeighScore
Boston Medical Group vs This Gen Wellness
The verdict
Boston Medical Group takes it — 61.9/100 to 56.9/100.
Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Boston Medical Group | This Gen Wellness |
|---|---|---|
| WeighScore | 61.9/100 | 56.9/100 |
| Grade | C | C |
| Scorecard rank | #279 | #405 |
| Semaglutide | $199/mo (starting strength, rising with dose, compounded) | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | 7 states | 1 state |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #279 · C
Strengths
- An established medical group with a defined 12-week programme rather than an open-ended subscription
- The price range and the 12-week total are both published, once you reach the costs page
- Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight
Where it loses points
- The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
- The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
- The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
- Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Graded #405 · C
Strengths
- Requires a synchronous live audio-video visit with a New York-licensed clinician — prescriptions are never issued from the intake form alone
- Assessment and clinician review are free; you only pay if treatment is prescribed and you choose to proceed
- Names its legal entity (ThisGen, LLC) and specifies New York governing law in its terms
- No long-term contracts — plans can be paused or stopped
- The same clinician follows your care, with ongoing secure messaging between visits
Where it loses points
- Publishes no prices at all — 'We don't list flat prices on the website'; cost is disclosed only after a clinician reviews your assessment
- Serves New York only — 'we currently operate exclusively for patients located in New York'
- Dispensing pharmacies are not named, only described as 'licensed U.S. pharmacies'
- Does not state whether its semaglutide and tirzepatide are compounded or brand-name
- Does not bill insurance; verifying any reimbursement is the patient's responsibility
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.